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Abstract
We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other
gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical
Oncology (ASCO). We have discussed the scientific findings and the impact on practice guidelines
and ongoing clinical trials. The report on KRAS status in patients with metastatic CRC receiving
epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in
National Comprehensive Cancer Network guideline that recommends only patients with wild-type
KRAS tumor should receive this treatment. The results of double biologics (bevacizumab and anti-
EGFR antibody) plus chemotherapy as first-line treatment in patients with metastatic CRC has
shown a worse outcome than bevacizumab-based regimen. Microsatellite Instability has again been
confirmed to be an important predictor in patients with stage II colon cancer receiving adjuvant
treatment.
Adjuvant gemcitabine therapy for pancreatic cancer was investigated by the CONKO-001 study;
this resulted in superior survival as compared with observation and can be regarded as an
acceptable option, without the addition of radiotherapy. The addition of bevacizumab to
gemcitabine and erlotinib was not supior to gemcitabine and erlotinib for advanced disease.
Second-line therapy for advanced pancreatic cancer with 5-fluorouracil and oxaliplatin resulted in
a survival benefit. Irinotecan plus cisplatin and paclitaxel plus cisplatin result in similar survival when
combined with radiotherapy for esophageal cancer. The novel fluoropyrimidine S1 appears to be
active in gastric cancer, as a single agent or as combination therapy. Adjuvant intraperitoneal
mitomycin-C may decrease the incidence of peritoneal recurrence of gastric cancer. Sorafenib is
an effective agent in Asian patients with hepatocellular carcinoma secondary to hepatitis B; its utility
in child's B cirrhosis remains to be proven. Sunitinib is also an active agent in hepatocellular
carcinoma, and may represent an alterative to sorafenib for advanced disease. These and other
important presentations from the 2008 ASCO annual meeting are discussed in this article.
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Colorectal cancer
Colorectal cancer (CRC) is among the top three most
common malignancies and cancer-related death in West-
ern world including United States [1]. In 2008, it is esti-
mated about 150,000 new cases, and approximate 50,000
patients die from this disease. The mortality for this dis-
ease has decreased slightly over the past three decades,
mainly due to improvement in screening and treatment.
For patients with early stage disease, surgery is the main
treatment, and frequently patients will benefit from adju-
vant treatment. The selected presentations from 2008
annual meeting of American Society of Clinical Oncology
(ASCO) are grouped into three categories: metastatic
CRC, adjuvant chemotherapy in stage II/III colon cancer,
and neurotoxicity and efficacy with intermittent oxalipla-
tin and use of calcium and magnesium.
Metastatic colorectal cancer
KRAS Mutation Predicts Lack of Response to Epidermal 
Growth Factor Receptor Antibody Treatment
Cetuximab and panitumumab are epidermal growth fac-
tor receptor (EGFR) targeted antibodies approved for clin-
ical use in patients with metastatic CRC. Ligand binding
of the EGFR activates the RAS/RAF/MAPK, STAT, and
PI3K/AKT signaling pathways, which modulate cellular
proliferation, angiogenesis, and survival. However, the
level of EGFR expression as measured by immunohisto-
chemistry does not predict clinical benefit [2].
KRAS, the human homolog of the Kirsten rat sarcoma-2
virus oncogene, encodes a small GTP-binding protein,
and acts as signal transducer in response to ligand binding
of growth factor receptor, including EGFR [3]. KRAS can
harbor oncogenic mutation, mostly in codon 12 and 13,
that yields a constitutively active protein, and such muta-
tion is found in approximately 30% to 50% of CRC [4].
Several retrospective analyses of tumor samples in CRC
patients receiving anti-EGFR antibody treatment have
shown that patients with mutated KRAS did not benefit
from anti-EGFR therapy [5,6]. Three clinical studies ana-
lyzing KRAS status retrospectively in metastatic CRC
patients have further supported this finding.
The CRYSTAL study is a phase III study comparing first-
line chemotherapy with a regimen of 5-fluorouracil (5-
FU), leucovorin (LV) and irinotecan, known as FOLFIRI,
with or without cetuximab. At 2007 ASCO annual meet-
ing, data from the CRYSTAL study was first presented,
which showed that addition of cetuximab to FOLFIRI
increased response rate (RR) by 8% and prolonged pro-
gression-free survival (PFS) by 0.9 months [7]. At plenary
session of 2008 ASCO annual meeting, Dr. Eric Van Cut-
sem presented a retrospective analysis of KRAS data in
archived tumor tissues obtained from 540 of the 1,198
patients enrolled in CRYSTAL study [8]. Mutated KRAS
was detected in 192 patients (36%), and in these patients
adding cetuximab to FOLFIRI did not improve RR or PFS.
In patients with tumor expressing wild-type KRAS, adding
cetuximab to FOLFIRI improved median PFS (9.9 vs. 8.7
months for patients receiving FOLFIRI, p = 0.017), and RR
(59.3% vs. 43.2% for patients receiving FOLFIRI alone, p
= 0.0025). In contrast, there was no benefit at all in RR or
PFS among patients with mutant K-RAS receiving FOLFIRI
plus cetuximab vs. FOLFIRI alone.
The OPUS trial is a phase II study enrolling 337 patients
and comparing FOLFOX (a regimen of 5-FU, LV and oxali-
platin) to FLOFOX plus cetuximab as first-line treatment
in patients with metastatic CRC. The initial finding
reported in 2007 ASCO annual meeting, showed an
increased RR when cetuximab was added to FOLFOX, but
this did not turn into better PFS [9]. In 2008 ASCO annual
meeting, Dr. Carsten Bokemeyer presented the KRAS anal-
ysis of tumor tissues from 233 patients in this study, and
KRAS mutation was detected in 42% [10]. In patients with
wild-type KRAS tumor, RR was 61% in FOLFOX plus
cetuximab group vs. 37% in FOLFOX (p = 0.011), and this
turned into improvement in median PFS (7.7 months vs.
7.2 months, p = 0.016). In patients with mutant KRAS, RR
was worse in FOLFOX plus cetuximab (33% vs. 49% in
FOLFOX, p = 0.11), and this turned into significantly
worse median PFS (5.5 months vs. 8.6 months in FOL-
FOX, p = 0.019).
Skin toxicity has previously been shown to correlate with
clinical benefits such as RR, PFS and overall survival in
patients with advanced CRC receiving anti-EGFR antibody
[11]. The EVERST study is to determine whether dose-
escalation of cetuximab based on skin toxicity in combi-
nation with irinotecan could improve efficacy in patients
who failed irinotecan-based therapy. After 22 days of
standard dose of cetuximab with irinotecan, patients with
grade 0/1 skin reactions were randomized to receive com-
bination of irinotecan plus either standard dose of cetuxi-
mab (250 mg/m2 weekly), or escalated doses of cetuximab
(50 mg/m2 increase every 2 weeks till 500 mg/m2 weekly
or more than grade 2 skin toxicity). In 2007 ASCO annual
meeting, Dr. Sabine Tejpar showed that increased dose of
cetuximab improved RR, but was associated with a dou-
bling of grade 3/4 diarrhea and grade 2 or higher skin tox-
icity [12]. In 2008 ASCO annual meeting, Dr. Tejpar
presented a retrospective analysis of KRAS status in
archived tumor tissues from 148 (including 77 of 89 ran-
domized) patients in this study, and mutation was identi-
fied in 39% [13]. For patients with wild-type KRAS, the RR
was 21.1% on standard cetuximab vs. 46.4% on escalated
cetuximab doses. However, none of the patients with
mutated KRAS in either arm achieved a response. The
severity of skin rash did not have any association with
KRAS status. The findings from this study suggest skin tox-Journal of Hematology & Oncology 2009, 2:9 http://www.jhoonline.org/content/2/1/9
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icity and KRAS status are independent predictors of out-
come for anti-EGFR antibody treatment.
The retrospective analyses of KRAS data from CRYSTAL,
OPUS and EVEREST have further demonstrated patients
with K-RAS mutant CRC do not benefit from anti-EGFR
antibody treatment. The addition of cetuximab to FOLF-
IRI or FOLFOX as first-line treatment only benefits
patients with wild-type KRAS tumors, however the opti-
mal sequence of biological therapy with chemotherapy in
this population remains to be determined. The KRAS data
has changed the paradigm of anti-EGFR antibody treat-
ment in CRC. National Comprehensive Cancer Network
has recently revised its CRC practice guideline, and recom-
mends CRC patients with know KRAS mutations should
not be treated with anti-EGFR antibody alone or in com-
bination with other anticancer agents [14]. The European
Medicines Agency has recognized these findings, and
restricts the use of anti-EGFR antibody in CRC patients
only with wild-type KRAS tumors.
National Cancer Institute (NCI) has suspended all ongo-
ing U.S. cooperative group studies involving anti-EGFR
antibody in CRC since June 2008 [15]. NCI has amended
N0147 study, which is an adjuvant trial comparing cetux-
imab plus FOLFOX vs. FOLFOX in patients with stage III
colon cancer after surgery. After amendment, only
patients with wild-type KRAS tumors will be randomized
for protocol treatment [16,17].
Worse Outcome for Combined Anti-EGFR and Anti-VEGF 
Antibody Therapy in the First-Line Treatment
Fluoropyrimidine-based chemotherapy plus the anti-vas-
cular endothelial growth factor (VEGF) monoclonal anti-
body bevacizumab is the standard front-line treatment for
patients with advanced CRC. Data from the BOND2 study
has demonstrated that the use of the bevacizumab and
cetuximab in combination with irinotecan-based chemo-
therapy is feasible and potentially more efficacious than
irinotecan plus cetuximab in patients with metastatic CRC
refractory to irinotecan-based therapy [18]. The PACCE
trial was conducted to examine the role of double anti-
body treatment in patients with advanced CRC by com-
paring bevacizumab and chemotherapy (FOLFOX or
FOLFIRI) with or without panitumumab as initial treat-
ment. The results of PACCE trial showed increased RR but
inferior PFS in patients receiving double antibody with
chemotherapy [19]. The interim analysis of KRAS status in
the subgroup of FOLFIRI and bevacizumab has shown the
increased RR associated with panitumumab was only seen
in patients with wild-type KRAS.
In 2008 ASCO annual meeting, a second phase III rand-
omized study, CAIRO-2, testing the role of combining
EGFR and VEGF antibody with chemotherapy as the first
-line treatment in patients with advanced CRC, was pre-
sented by Dr. Punt [20]. In this study, capecitabine, oxali-
platin, and bevacizumab with or without cetuximab were
compared. Median PFS was significantly reduced in
patients on double antibody with chemotherapy (9.6
months) compared with bevacizumab plus chemotherapy
(10.7 months, p = 0.018), but there was no differences in
RR and overall survival (OS) between these 2 groups. In
patients with mutated KRAS, the addition of cetuximab to
chemotherapy and bevacizumab resulted in significantly
decreased PFS (8.6 months vs. 12.5 months, p = 0.043).
There was no difference in PFS in those with K-RAS wild-
type tumors.
Data from both PACCE and CAIRO-2 studies have indi-
cated no benefit of adding anti-EGFR antibody to bevaci-
zumab and chemotherapy in the first-line treatment of
advanced CRC, and patients with mutant KRAS tumors
had worse outcome on double antibodies and chemother-
apy compared to bevacizumab and chemotherapy. As a
result of these two reports, NCI has suspended two on-
going phase III cooperative group studies, Cancer and
Leukemia Group B (CALGB) 80405 and South West
Oncology Group (SWOG) 0600, in June 2008 [16]. Both
studies are designed to compare chemotherapy with dou-
ble antibodies (EGFR and VEGF) or single antibody
(EGFR or VEGF) in patients with metastatic CRC receiving
first-line or second-line treatment. After a detailed analy-
sis of toxicity date, CALGB 80405, which is a first-line
study FOLFOX with bevacizumab, or cetuximab, or with
the combination of bevacizumab and cetuximab in
patients with metastatic CRC, has reactivated in December
2008. This study has reached approximately 60% of
accrual goal (~2,300 patients). Combined biologic ther-
apy with anti-EGFR and anti-VEGF antibodies is not rec-
ommended for patients with metastatic CRC outside of
the clinical trial setting.
Role of Pre-operative FDG-PET in Surgical Treatment of 
Colorectal Liver Metastases
Staging CRC patients by 2- [18F] fluoro-2-deoxy-D-glu-
cose (FDG) and positron emission tomography (PET) is
thought to be better than CT scan, however the evidence
of improved clinical management and outcome is lacking.
Wiering et al. reported a randomized controlled study
enrolling 150 CRC patients with liver metastasis planning
for surgical resection [21]. Patients were randomized to
CT imaging only or CT and FDG-PET imaging before sur-
gery for staging. Primary endpoint was futile laparotomy,
defined as any laparotomy that revealed benign disease or
that did not result in a disease free survival period longer
than 6 months. Addition of PET to CT imaging identified
20% patients with benign or additional diseases before
surgery and prevented 5 patients from surgery (2 benign
diseases and 3 with extra-hepatic diseases). The number ofJournal of Hematology & Oncology 2009, 2:9 http://www.jhoonline.org/content/2/1/9
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futile laparotomy was reduced from 45% in the group
without PET to 28% in the group with PET. This study
concluded that addition of FDG- PET to the work-up for
surgical resection of colorectal liver metastases prevented
unnecessary surgery in one out of six patients. FDG-PET is
recommended to be used routinely before planned liver
resection for CRC metastases.
FOLFIRI in Patients with Resected Liver Metastasis from 
CRC
Chemotherapy is frequently administered after complete
resection of liver metastases from CRC, but the optimal
regimen is yet to be established. Dr. Marc Ychou presented
preliminary finding from CPT-GMA-301 study, which was
conducted to compare 6-month of adjuvant chemother-
apy with 5-FU/LV vs. FOLFIRI in this setting with DFS as
the primary endpoint [22]. This randomized study
enrolled 306 patients with complete resection of exclu-
sively liver metastasis without prior treatment for meta-
static disease. Prior adjuvant chemotherapy except
irinotecan-based regimen was allowed. More grade-3/4
toxicities were observed in FOLFIRI arm, especially neu-
tropenia. There was no statistical difference in 2-year DFS
(46% for 5-FU/LV [95% confidence interval (CI), 38%–
54%] vs. 51% with FOLFIRI [95% CI, 42%–58%] and 3-
year OS (72% for 5-FU/LV [95% CI, 63%–79%] vs. 73%
for FOLFIRI [95% CI, 64%–80%] between these 2 arms.
However, there was a trend toward better outcome in
FOLFIRI arm if patients started chemotherapy within 6
weeks of surgery (HR 0.75; p = 0.18). Therefore, rand-
omized trial incorporating biological agents with chemo-
therapy is urgently needed in this setting to define the
optimal regimen.
Adjuvant chemotherapy in stage II and III colon 
cancer
The Use of Bevacizumab
Allegra et al. reported the initial safety report of NSABP C-
08, a phase III randomized study enrolling 2,710 patients
to compare a modified FOLFOX regimen known as
mFOLOX6 (every 2 weeks for 12 cycles) vs. bevacizumab
and mFOLFOX6 (every 2 weeks for 12 cycles then bevaci-
zumab alone every 2 weeks for 14 cycles) as adjuvant ther-
apy in patients with stage II/III colon cancer after surgery
[23]. A significantly higher percentage of patients com-
pleted 10 or more cycles of chemotherapy and received a
higher cumulative oxaliplatin dose in the bevacizumab
arm. The median duration of bevacizumab therapy was
11.5 months. Toxicities were well balanced in the 2
groups, with overall rate of grade 4/5 toxicities 15.2% and
15.3%, including death of 1.0% and 1.3%, respectively.
There was no difference in treatment-associated mortality
(excluding death after relapse or second primary) within
6 months or 18 months after randomization. Toxicities
that were significantly increased in the bevacizumab arm
included sensory neuropathy (which could be attributed
by higher cumulative dose of oxaliplatin), hypertension,
pain, proteinuria, hand-foot syndrome, and wound heal-
ing complications. There were no significant differences in
the incidence of gastrointestinal perforation, hemorrhage,
or arterial thrombotic events between these 2 arms. Long-
term follow-up for efficacy and potential delayed side
effects is ongoing.
Role of Oxaliplatin
Wolmark and colleagues presented an update on the pre-
viously reported NSABP C-07 trial [24]. The trial was con-
ducted to compared the efficacy of adjuvant
chemotherapy with bolus 5-FU/LV vs. 5-FU/LV and oxali-
platin (FLOX) in patients with stage II and III colon can-
cer. Disease-free survival (DFS) was the primary endpoint
and OS the secondary endpoint. The investigators previ-
ously reported a 3-year DFS that significantly favored
FLOX over 5-FU/LV (76.5% and 71.6%, respectively, P =
.004) at the 2005 ASCO annual meeting [25]. The 5-year
OS was reported at the 2008 ASCO annual meeting. There
was improvement of 5-year OS for FLOX (80.3%) vs. 5-
FU/LV (78.3%), but not statistically significant (p =
0.061). Longer follow-up is needed to determine signifi-
cant survival benefit in this study since patients with
recurrent CRC are having longer survival due to the
improvement of treatment outcome. This finding from
NSABP C-07 is consistent with the results from the Multi-
center International Study of FOLFOX in the Adjuvant
Treatment of Colon Cancer (MOSAIC) reported in 2007
ASCO annual meeting [26]. In MOSAIC study, the OS in
stage III patients was not statistically different till median
of 6-year follow-up, with 4.4% better in FOLFOX (73.0%)
vs. 5-FU/LV (68.6%; hazard ratio [HR] 0.80; p = 0.029).
Both studies have confirmed the benefit of adding oxali-
platin to 5-FU based adjuvant chemotherapy for stage III
colon cancer by showing superior 3-year DFS in oxalipla-
tin arm. Three-year DFS remains a very important end-
point and continues to be a surrogate endpoint for OS for
adjuvant trial in colon cancer,
Microsatellite Instability
The benefit of adjuvant chemotherapy is still debatable
for stage II colon cancer. The United Kingdom QUASAR
study has shown chemotherapy with 5-FU and LV in
patients with stage II CRC can provide a small improve-
ment (~4%) in rates of recurrence and OS compared to
patients on observation [27]. However, in MOSAIC study,
FOLFOX did not improve survival in patients with stage II
colon cancer. This indicates a need for identifying high-
risk patients with stage II colon cancer who may benefit
from adjuvant chemotherapy. It has been shown that 5-
FU-based adjuvant chemotherapy may not benefit
patients with stage II or III colon cancer exhibiting micro-
satellite instability (MSI) [28].Journal of Hematology & Oncology 2009, 2:9 http://www.jhoonline.org/content/2/1/9
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In 2008 ASCO annual meeting, Sargent et al. presented an
analysis of 491 patients from five clinical trials randomiz-
ing patients with stage II and III colon cancer to either 5-
FU based adjuvant chemotherapy or no post-operative
treatment [29]. Those with high MSI were stratified as
having deficient mismatch repair (dMMR) and those with
microsatellite stability or low MSI were stratified as having
proficient mismatch repair (pMMR). Among these
patients, stage II was 49% and dMMR was 15%. In
patients with pMMR, adjuvant therapy with 5-FU trans-
lated into an increase in DFS and OS in stage III. Con-
versely, patients with dMMR derived no benefit from
adjuvant 5-FU treatment either in stage II or III. This anal-
ysis was further pooled with the previously reported data
by Ribic et al. [28] with patients number totaling 1,027,
and the 5-year DFS and OS were worse in patients with
stage II colon cancer with dMMR treated with 5-FU ther-
apy vs. observation alone. This study has further sup-
ported that MSI can be used to predict who will benefit
from adjuvant 5-FU chemotherapy for colon cancer, par-
ticularly in patients with stage II disease. The ongoing
Eastern Cooperative Oncology Group (ECOG) 5202
study is a perspective study in stage II colon cancer to
identify high-risk patients for adjuvant treatment using
molecular marker analysis including MSI and tumor 18q
loss of heterozygosity [30]. The result of ECOG 5202 will
provide a definitive answer on how to use molecular
markers in selecting high-risk patients for adjuvant treat-
ment in patients with stage II colon cancer.
Neurotoxicity and efficacy with intermittent 
oxaliplatin and use of calcium and magnesium
The sensory neuropathy associated with cumulative oxali-
platin treatment frequently interrupts with the adminis-
tration of oxaliplatin-based regimen for CRC. Two studies
presented at the 2008 ASCO annual meeting examined
the strategy of using calcium and magnesium, and one
study also examined intermittent administration of oxali-
platin in minimizing neurotoxicity from oxaliplatin.
The Combined Oxaliplatin Neurotoxicity Prevention Trial
(CONcePT) randomized patients receiving first-line ther-
apy for metastatic CRC to either continuous or intermit-
tent FOLFOX plus bevacizumab. The intermittent arm
differed from the continuous arm in that oxaliplatin was
stopped after 8 cycles in patients who had at least stable
disease, then was re-started after another 8 cycles of main-
tenance therapy with bevacizumab and infusional 5-FU/
LV or tumor progression during maintenance treatment.
Patients in both arms were also randomized to receive
intravenous calcium gluconate and magnesium sulfate
(CaMg) before and after oxaliplatin treatment. This study
was discontinued prematurely due to interim analysis sug-
gesting there were significantly lower RR in patients
receiving CaMg. However, a subsequent independent
radiology review did not find any evidence of detrimental
effect from CaMg on the activity of FOLFOX plus bevaci-
zumab. An analysis of the 139 patients who received treat-
ment per protocol was performed and presented at 2008
ASCO annual meeting [31]. Time to treatment failure
(TTF), the primary endpoint of the trial, was significantly
longer in patients receiving the intermittent oxaliplatin
schedule, 5.6 months vs. 4.2 months in those receiving
continuous treatment (HR 0.58; p = 0.0025). Severe neu-
rotoxicity was significantly reduced in the intermittent
oxaliplatin arm (10%) compared with the continuous
oxaliplatin arm (24%, p = 0.048). Treatment delays or
dose reductions for neurotoxicity were more than twice as
frequent in patients on the continuous oxaliplatin arm.
There was no significant effect of CaMg or placebo on TTF
or PFS. The investigators concluded that intermittent
oxaliplatin administration was associated with a signifi-
cant improvement of TTF compared with continuous
oxaliplatin, without compromising PFS. CaMg reduced
the severity of neuropathy and did not compromise the
activity of FOLFOX plus bevacizumab. Taken together
with data from the previously reported OPTIMOX1 &
OPTIMOX2 trials [32,33], CONcePT trial provides further
evidence that intermittent oxaliplatin-based therapy
should be considered the standard of care in the first-line
treatment of metastatic CRC.
N04C7 was designed as a placebo-controlled phase III
study to prospectively evaluate the activity of CaMg as
neuroprotectant against cumulative oxaliplatin-related
peripheral sensory neurotoxicity [34]. Patients undergo-
ing adjuvant FOLFOX chemotherapy were randomized to
receive CaMg or placebo. This trial accrued only 104 of
300 planned patients due to the early closure of the CON-
cePT trial. Despite the early closure, a significantly
decreased incidence of grade 2 or higher neurotoxicity was
observed in patients receiving CaMg (22% vs. 41% in the
placebo group, p = 0.038). The time to development of
grade 2 or higher neurotoxicity was also prolonged in the
CaMg group. Additionally, there was no difference in side
effects between CaMg and placebo group. The finding
from this study indicates that CaMg can be considered as
a routine neuroprotective treatment when used in con-
junction with oxaliplatin-based chemotherapy in the set-
ting of adjuvant therapy for CRC.
Non-colorectal gastrointestinal cancers
Non-colorectal gastrointestinal cancers have a significant
burden world-wide. Modern multimodal approaches that
integrate surgery, radiation and systemic therapy, the
development of new cytotoxic agents along with anti-
EGFR and anti-VEGF therapies have led to a significant
survival improvement for colorectal cancer patients.
Advances have been limited however, in the case of non-
colorectal gastrointestinal cancers. The research presentedJournal of Hematology & Oncology 2009, 2:9 http://www.jhoonline.org/content/2/1/9
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at the 2008 ASCO annual meeting indicates that progress
in these cancers is forthcoming. Abstracts from the annual
meeting are grouped below into categories based on dis-
ease sites: pancreatic, esophagogastric, and hepatobiliary.
Pancreatic cancer
Adjuvant Therapy for Pancreatic Cancer
Surgical resection remains the only potential curative ther-
apy for pancreatic cancer patients. However, 5-year sur-
vival for surgically resected patients is 30% only and most
patients die of disseminated disease. Therefore, effective
adjuvant strategies are needed. The Gastrointestinal
Tumor Study Group (GITSG) 9173 trial indicated that
post-operative 5-FU and radiotherapy extended the
median overall survival to 20 months, as compared with
12 months with observation alone. Similar results were
reported subsequently by the Johns Hopkins and Euro-
pean Organization for Research and Treatment of Cancer
(EORTC) and 5-FU -based chemoradiation became the
standard-of-care for nearly two decades [35]. The Euro-
pean Study Group for Pancreatic Cancer (ESPAC-1) has
been however, a paradigm-changing trial which was a
multinational effort conducted in 11 European nations
[36]. This study indicated for the first time that adjuvant
systemic chemotherapy led to a superior survival as com-
pared with the either the no-chemotherapy or the chemo-
radiotherapy groups. Although the study methodology of
ESPAC-1 is regarded as controversial, this trial has demon-
strated that a median survival of 20 months could be
achieved with adjuvant 5-FU chemotherapy alone, with-
out the addition of radiation. Therefore, adjuvant chemo-
therapy is regarded as the standard adjuvant treatment
after surgical resection of the pancreas in Europe. The
recent Radiation Therapy Oncology Group (RTOG) 9704
indicated that adjuvant gemcitabine followed by chemo-
radiation was superior to 5-FU for pancreatic head carci-
nomas [37,38]. The CONKO-1 study was a multi-center,
European trial which randomized 368 patients with surgi-
cally resected pancreatic cancer to post-operative gemcit-
abine for 6 months vs. observation. Previous analyses
revealed the adjuvant gemcitabine to be well-tolerated
and an improvement in DFS. The final analysis of the
CONKO-1 study was presented at the 2008 ASCO annual
meeting [39]. There was a statistically significant improve-
ment in DFS (13 vs. 7 months) with adjuvant gemcitab-
ine. The improvement in overall survival however, was
very modest (2 month-improvement with gemcitabine).
Five-year survival was 21% for gemcitabine and 0% with
observation. Adjuvant gemcitabine chemotherapy effec-
tively improved DFS, irrespective of lymph node, margin
status or T stage. This study highlights: a. the improved
survival of patients treated with surgery alone (20
months), b. the limited benefit provided by any adjuvant
strategy and c. that adjuvant therapy is relatively ineffec-
tive in the prevention of early mortality (survival curves
separate only after 18 months). The American College of
Surgeons Oncology Group (ACOSOG) phase II study
Z05031 explored a novel combination of 5-FU, cisplatin,
interferon and radiotherapy in the adjuvant setting, based
on the results of a previous study conducted by Picozzi, et
al. which indicated an impressive OS with this regimen
[40]. The ACOSOG Z05031 enrolled 90 patients, of
whom only 56% received all 3 cycles of therapy due to
treatment-related toxicity. Despite the use of an intensive
chemoradiation strategy, local recurrences occurred in
46% of the patients. The median OS for all patients in this
study was 27 months, which at first glance appears supe-
rior to historical standards. However, the relatively com-
mon grade 3 toxicities (96%) and modest survival
improvement (4 months more than the treatment arm in
CONKO-1) argues against the widespread use of this reg-
imen.
Together, the CONKO-1 and the ESPAC-1 studies argue
against the use of standard, post-operative, adjuvant radi-
otherapy for pancreatic cancer. Preoperative chemoradia-
tion strategies that decrease margin-positive resections
and pre-select patients with better cancer biology for
resection deserve further exploration.
Advanced Pancreatic Cancer
The addition of erlotinib to gemcitabine improved OS as
compared with gemcitabine alone, in the PA.3 study,
although the median survival increase was very modest
(5.9 to 6.4 months with the addition of erlotinib) [41].
The addition of cetuximab or bevacizumab to gemcitab-
ine, on the other hand did not result in any survival
improvement. The AVITA study was a randomized, phase
III study that included 607 patients with metastatic pan-
creatic cancer and explored the addition of bevacizumab
to the gemcitabine + erlotinib combination[42]. Study
participants received first-line treatment with gemcitab-
ine, erlotinib and placebo or gemcitabine, erlotinib and
bevacizumab.
There was no significant prolongation of survival with the
addition of bevacizumab, although DFS was significantly
improved (from 3.6 to 4.6 months). Bevacizumab was
reported to be safe in this combination, despite an
increase in the incidence of epistaxis, hypertension and
proteinuria. Interestingly, there was no reported increase
in thrombotic events with bevacizumab. The AVITA study
suggests that antiangiogenic strategies may have merit in
the treatment of advanced pancreatic cancer, although the
margin of benefit with bevacizumab is modest. Therefore,
it is imperative that we identify patient subgroups that
may benefit from such an approach.
Kindler et al. investigated a multi-targeted strategy against
both the EGFR and VEGF in a randomized phase II study.Journal of Hematology & Oncology 2009, 2:9 http://www.jhoonline.org/content/2/1/9
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Pancreatic cancer patients (n = 139) received gemcitabine,
bevacizumab and erlotinib or gemcitabine, bevacizumab
and cetuximab [43]. They noted that early hypertension
correlated with response. There was no significant differ-
ence between the two arms in either OS or PFS. Therefore,
cetuximab or bevacizumab cannot be recommended for
pancreatic cancer at the current time outside of an investi-
gational setting.
Gemcitabine has become the standard therapy for
advanced pancreatic cancer, since its approval almost a
decade ago. Subsequent investigational strategies have
included the addition of other, targeted agents to gemcit-
abine. There have been very few attempts to address the
role of alternative cytotoxic agents (which may represent
better platforms for the addition of targeted therapies)
other than gemcitabine in the first-line setting. The FFCD
group randomized 202 patients with advanced, untreated
pancreatic cancer to gemcitabine or 5-FU plus cisplatin
[44]. Patients received therapy until progression, after
which they could cross to the opposite arm. There were no
significant differences in survival between the two arms.
One-year and two-year survival figures were also identical
between the gemcitabine and 5-FU plus cisplatin arms.
Although it is unlikely that 5-FU and cisplatin will replace
gemcitabine due to toxicity concerns, these data provide
the rationale for non-gemcitabine containing regimens in
the first-line setting based on pharmacogenomic profile.
Second-Line Therapy
There are no standard second-line regimens for advanced
pancreatic cancer, after gemcitabine failure. However,
capecitabine, capecitabine and oxaliplatin (CAPOX), and
FOLFOX are commonly used. The CONKO-3 study rand-
omized 168 patients who had gemcitabine-refractory pan-
creatic cancer to 5-FU, LV and oxaliplatin (OFF) or 5-FU
and LV (FF) [45]. The study was powered at 90% to detect
an improved OS by 2 months in the OFF arm. Both regi-
mens were tolerable, with the exception of higher neurop-
athy in the OFF arm. The median OS in the OFF arm was
28 weeks, and that of the FF arm was 13 weeks, thereby
fulfilling the study hypothesis. There was also a significant
prolongation of PFS in the treatment arm (13 vs. 9 weeks).
OFF should now be regarded as a standard second-line
regimen for pancreatic cancer.
Novel Agents for Pancreatic Cancer
Nanoparticle albumin-bound (Nab)-paclitaxel is a novel
paclitaxel formulation which is currently approved for the
treatment of breast cancer. Due to the nano-size and pres-
ence of albumin, which attracts the particle to tumor sites,
the penetration of cytotoxic agents bound to the nanopar-
ticle is very high, possibly leading to a better anti-tumor
response. Preclinical data indicated that increased expres-
sion of Secreted Protein and Rich in Cysteine (SPARC)
within tumors resulted in improved anti-tumor response
to Nab-paclitaxel. Pancreatic cancer overexpresses SPARC
protein and impressive partial responses (PRs) were seen
in a phase I pancreatic cancer study of Nab-paclitaxel +
gemcitabine [46]. Nine PRs occurred in 20 treated
patients, after a median of 2 cycles. This combination
appears to have promising activity in pancreatic cancer.
The CALGB presented the results of a single-arm phase II
study of sunitinib for patients with advanced pancreatic
cancer who had previously been treated with gemcitabine-
based therapy. No responses were reported in 77 treated
patients, and stable disease resulted in 7 patients [47]. The
California consortium reported similar disappointing
results with sorafenib when combined with gemcitabine
[48]. In this randomized study, chemo-naïve pancreatic
cancer patients received sorafenib as a single agent or as a
combination with gemcitabine. No responses resulted
with sorafenib alone and the median survival of the gem-
citabine + sorafenib arm was 6 months only. Both
sunitinib and sorafenib have insufficient anti-tumor activ-
ity in pancreatic cancer and do not merit further study in
this disease. Mammalian Target of Rapamycin (mTOR)
has emerged as an important target for therapy in renal
cell carcinoma. Wolpin et al. treated 31 gemcitabine-
refractory pancreatic cancer patients with the mTOR-
directed oral agent, everolimus 10 mg once daily.
Although the agent was tolerable, there were no responses
and disease stability was uncommon [49].
Locally Advanced Pancreatic Cancer
Gemcitabine in combination with radiotherapy (50.4 Gy
in 28 fractions) was compared with gemcitabine chemo-
therapy (alone) for locally advanced pancreatic cancer by
the Eastern Cooperative Oncology Group (ECOG) 4201
study. Although this study was closed early (74 patients
enrolled out of planned size of 316 patients) due to poor
enrollment, there was a statistically significant median-
survival improvement in the combination-therapy arm
(9.2 months with gemcitabine and 11 months with gem-
citabine and radiation). Unfortunately, this very modest
survival improvement occurred at the expense of 40%
grade 4 gastrointestinal/hematological toxicities in
patients receiving chemoradiation. Kim et al. reported the
results of a phase II study of gemcitabine, oxaliplatin and
radiotherapy, followed by gemcitabine chemotherapy in
53 patients with locally advanced pancreatic cancer [50].
The median survival reported in this trial was 9.3 months,
at the cost of substantial toxicity. These studies argue
against upfront chemoradiation for locally advanced pan-
creatic cancer. Chemoradiation may be best utilized after
induction chemotherapy for locally advanced cancers.
The GERCOR phase II and III trials have indicated that
induction chemotherapy can identify patients who are
most likely to benefit from radiotherapy [51]. PancreaticJournal of Hematology & Oncology 2009, 2:9 http://www.jhoonline.org/content/2/1/9
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cancer patients with stable disease after 3 months of
chemotherapy received chemoradiation in these studies
and their median survival was 15 months, as compared
with 11 months for those receiving chemotherapy alone.
Patient-Tailored Therapy for Pancreatic Cancer
Investigators at Johns Hopkins presented data on their
preclinical model termed PanXenoBank, which uses surgi-
cally resected pancreatic adenocarcinoma to generate
xenograft in mice [52].
This xenograft serves as an in vivo platform for drug testing
and provides data that can be used prospectively to treat
patients. Of the 90 patients whose cancers were
xenografted, 18 failed to engraft and preliminary results in
the rest indicated that a tailored-approach, using uncon-
ventional agents such as mitomycin-C was possible.
While the data in this regard is premature and the tech-
nique is labor-intensive, this strategy holds promise. The
MD Anderson group presented data on single nucleotide
polymorphisms (SNPs) of genes involved in gemcitabine
metabolism and showed that cytidine deaminase and
deoxycytidine kinase alleles were associated with an
improved survival, albeit at the cost of increased toxicity
[53]. Collisson et al. investigated gene expression profiles
from micro-dissected pancreatic resection specimens
using Affymetrix GeneChips and identified prognostic
groups, which were based on differentially expressed
genes [54]. They concluded that the disparity of outcomes
was due to intrinsic differences in tumor biology. These
data open avenues for targeting specific subgroups with
dose-intensive strategies.
Esophagogastric cancers
Preoperative vs. Post operative Adjuvant Therapy
The Japanese Oncology Group (JCOG) presented updated
data from the JCOG 9907 study, which randomized 330
patients with stage II or III esophageal cancer to pre-or
post-operative chemotherapy with 5-FU and cisplatin
[55]. In the post-operative arm, 30% of patients could not
complete chemotherapy, while 90% completed treatment
in the pre-operative arm. Only 4/160 patients had com-
plete pathologic response in the pre-operative arm. In an
early analysis of the trial, there appeared to be a significant
progression-free survival benefit in favor of the preopera-
tive arm. In an updated analysis in November 2007, how-
ever there was no reported benefit in PFS. In a subgroup
analysis, patients who were lymph node negative (N0),
appeared to benefit from preoperative therapy, while the
lymph node positive patients did not. In their prior study
JCOG 9204, patients with lymph node metastases bene-
fited from adjuvant chemotherapy [56]. These conflicting
results along with the large number of cases who did not
receive adjuvant therapy makes the findings of the present
study hard to interpret. Thus, despite this relatively large
study, it remains to be proven that pre-operative therapy
is superior to post-operative adjuvant therapy for esopha-
geal cancer.
Preoperative Therapy for Esophageal Cancer-Choice of 
Chemotherapy
Irinotecan plus cisplatin, paclitaxel plus cisplatin, and 5-
FU plus cisplatin are commonly used chemotherapeutic
combinations along with radiotherapy for the preopera-
tive treatment of esophageal cancer. The ECOG 1201 was
a randomized phase II study for paclitaxel plus cisplatin
vs. irinotecan plus cisplatin along with radiotherapy for
these patients [57]. All patients had rigorous preoperative
staging which included endoscopic ultrasound. There
were no significant differences in survival between the two
arms, irrespective of stage. Furthermore, the results did
not appear to be superior to those with 5-FU plus cispla-
tin.
Chemoradiation as Definitive Therapy for Squamous Cell 
Carcinoma of Esophagus
Stahl et al. reported the results of a randomized trial of
chemoradiation ± surgery for operable squamous cell car-
cinoma of the esophagus [58]. In their earlier report in
2005, they reported no improvement in survival with the
addition of surgery, although there was an improvement
in local control. In their updated analysis, 5 and 10-year
survival figures were presented [59]. There was no clear
survival difference at both time points between the surgi-
cal and non-surgical arms. Response to induction chemo-
therapy was the most important predictor of survival.
These long term follow-up data again suggest that
esophagectomy with its morbidities cannot be routinely
recommended for esophageal squamous cell cancer.
Intraperitoneal Adjuvant Therapy for Gastric Cancer
Peritoneal relapse occurs frequently in surgically resected
gastric cancer. Therefore, adjuvant intraperitoneal chemo-
therapy merits study. Kang et al. randomized 640 patients
with gastric cancer that had involved the serosa (at intraop-
erative evaluation) to intraperitoneal cisplatin, early mito-
mycin-C (administered on day 1) after surgery and an
extended schedule of doxifluridine (for 12 months) and
cisplatin, vs. delayed mitomycin-C (3–6 weeks post-opera-
tive) and a 3 month course of doxifluridine [60]. The
results indicated a significantly improved relapse free sur-
vival and OS in the intraperitoneal therapy arm. Unfortu-
nately, this study had several experimental elements,
including early administration of mitomycin-C, inclusion
of cisplatin and prolonged doxifluridine administration
besides the intraperitoneal therapy. Thus, it remains to be
proven if the survival improvement in the experimental
arm is secondary to intraperitoneal therapy only. A rand-
omized study wherein intraperitoneal chemotherapy is theJournal of Hematology & Oncology 2009, 2:9 http://www.jhoonline.org/content/2/1/9
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only experimental treatment is required to answer this
question.
Systemic Therapy for Advanced Gastric Cancer
Docetaxel, cisplatin and 5-FU (DCF) is a FDA-approved
regimen for gastric cancer, based on the results of the
V325 study, which proved the superiority of this regimen
as compared with 5-FU and cisplatin [61]. However, the
toxicity of this regimen limits its widespread use. There-
fore, Ridwelski et al. investigated the activity of docetaxel
and cisplatin administered on a 3 weekly schedule (with-
out 5-FU) and compared the activity of this regimen with
5-FU and cisplatin in a phase III study [62]. A total of 273
patients were enrolled, and the primary study endpoint
was prolongation of time to progression. At 12 months
follow-up, the RR and PFS were virtually identical in the
two arms and there was no significant difference in OS.
Neutropenia occurred more frequently with docetaxel and
cisplatin, while diarrhea was more likely with 5-FU and
cisplatin. DCF remains an acceptable standard regimen
based on these results. Alteration to a weekly schedule
(from 3-weekly) may ameliorate the toxicities of DCF.
Novel Agents for Esophagogastric Cancers
Cetuximab was investigated in second-line setting as a sin-
gle-agent in patients with metastatic esophageal cancer by
SWOG [63]. Marginal activity was noted with a PFS of less
than 2 months and OS of 4 months. When combined
with systemic chemotherapy however, in a randomized
phase II study of cetuximab ± cisplatin and 5-FU for met-
astatic squamous cancers of the esophagus, there was an
improved survival noted in the cetuximab containing arm
(9.5 vs. 5.5 months) [64]. S1 is an active agent in gastric
cancer and has synergistic anti-tumor activity with cispla-
tin and docetaxel (table 1).
Hepatobiliary cancers
Sorafenib
Sorafenib is a novel inhibitor of Raf kinase, VEGF receptor
(VEGFR) and platelet-derived growth factor receptor, and
has been recently approved for the treatment of advanced
hepatocellular cancer (HCC), based on the results of the
SHARP trial [65]. In this study, patients with child's A cir-
rhosis were enrolled and an approximate 3-month sur-
vival benefit was demonstrated in the sorafenib group vs.
the placebo group. In 2008 ASCO annual meeting, the
effectiveness of sorafenib was investigated in subpopula-
tions of hepatocellular carcinoma.
Raoul et al. studied the effect of sorafenib in ECOG per-
formance status (PS) 1 and 2 patients as a subanalysis
from the SHARP trial [66]. They noted that sorafenib was
tolerable in this group of patients. However, it remains
unclear if this advantage is applicable to ECOG PS 2 cases
specifically as this group of patients are often candidates
for supportive care only.
In Asian countries, the incidence of HCC is higher than in
the western nations and is more likely to be HBV-associ-
ated. Cheng et al. randomized 226 Asian patients with
HCC to sorafenib or placebo. Sorafenib significantly pro-
longed OS and PFS as compared with placebo [67]. The
degree of benefit seemed to be similar to that experienced
by the western patients, thus establishing this agent as a
standard therapy for HCC.
Abou-Alfa et al. presented the results of sorafenib therapy
in HCC patients with child's B cirrhosis [68]. In a phase II
study, 137 HCC patients with child's A/B cirrhosis
received the standard dose of 400 mg bid. They noted
comparable sorafenib pharmacokinetic profiles of child's
A and B groups. The median OS for child's B cases was 14
weeks and time to progression (TTP) was 13 weeks. There
was a more frequent worsening of hepatic function in the
Table 1: S1 Studies in Advanced Gastric Cancer
Abstract/author Study agents Patient number Study Design RR PFS OS
A4534/
Jeung et al.
S1, Docetaxel, Cisplatin 80 Randomized phase II Docetaxel + S1 
or Docetaxel + cisplatin
44%
24%
198 days
143 days
(p = 0.03)
NR
A4533/
Jin et al.
S1
Cisplatin
5-FU
230 Randomized phase III S1 vs. S1 + 
cisplatin vs. 5-FU + cisplatin
25%
38%
19%
(p = 0.021)
267 days
433 days
309 days
(p = 0.008)
NR
A4537/
Sato et al.
S1
Docetaxel
Cisplatin
31 Phase II study 87% 7.7 months 19 months
RR: Response rate; PFS: Progression-free survival; OS: Overall survival; NR: Not reported.Journal of Hematology & Oncology 2009, 2:9 http://www.jhoonline.org/content/2/1/9
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child's B cases. The utility of sorafenib in this group of
HCC patients remains to be proven.
Sunitinib
Sunitinib is a multi-targeted tyrosine kinase inhibitor that
is directed against VEGFR2 and has activity comparable to
that of sorafenib. Zhu et al. presented phase II data of 34
patients with HCC who received sunitinib in a dose of
37.5 mg daily. Median PFS was 4 months and OS 10
months [69]. Biomarkers may correlate with response;
elevated VEGF-C levels were associated with an improved
TTP and OS. Treatment with sunitinib decreased tumor
vascular permeability and plasma VEGFR2 levels.
Sunitinib is an active agent in hepatocellular carcinoma,
and may represent an alterative to sorafenib for advanced
disease. A phase III randomized study comparing
sunitinib vs. sorafenib as the first-line systemic treatment
in patients with inoperable HCC is currently underway.
Cholangiocarcinoma/periampullary cancer
Bevacizumab and erlotinib may have promising activity
in this chemo-refractory disease. In a preliminary analysis
of their multi-center phase II study, Holen et al. reported
4 PRs resulting from this biologic-only combination
among 20 assessed patients, and 4 cases with stable dis-
ease [70]. Cetuximab in combination with gemcitabine
and oxaliplatin resulted in either disease response of sta-
bility in the majority of cholangiocarcinoma patients; 6/
22 patients who were initially considered unresectable
had surgical resections after major responses [71]. Soraf-
enib results in disease stabilization in 30% of cholangi-
ocarcinoma patients in a phase II study reported by Dealis
et al. [72]. Toxicities however, were common in patients
with ECOG PS 2. Cholangiocarcinoma and gall bladder
cancers appear to be responsive to EGFR and VEGF inhib-
itors. A randomized study is required to determine the
role of targeted agents in this disease.
Periampullary cancers may have a better prognosis as
compared with pancreatic and biliary cancers. However,
the standard of care in this patient population remains to
be defined, due to the relative rarity of this disease. Over-
man et al. reported the efficacy results of a phase II study
of CAPOX in advanced periampullary cancer. An impres-
sive 50% RR and a median survival of 20 months was
recorded [73]. Grade 3/4 toxicities were fatigue, neuropa-
thy and myelosuppression. The addition of EGFR or VEGF
targeted therapy to CAPOX is worthy of study in this dis-
ease.
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